** Drug developer Biohaven's BHVN.N shares fall 4.1% to $35.66
** Co posts Q4 adj. loss of $1.71 per share compared with analysts' average estimate of a loss of $1.57, according to data compiled by LSEG
** Separately, co says its experimental drug, BHV-1300, reduced Immunoglobulin G, a type of antibody, by 84% in an early-stage study to treat an autoimmune condition called Graves' disease
** Co plans to initiate a mid-stage study in patients with the disease in mid-2025
** BHVN has fallen 21.4% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.